| Description |
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C)[1].
|
| Related Catalog |
|
| In Vitro |
MM 419447 exhibits high-affinity binding to T84 cells, resulting in a significant, concentration-dependent accumulation of intracellular cyclic guanosine-39,59-monophosphate (cGMP)[1].
|
| In Vivo |
MM 419447 (10 mg/kg; p.o.) treatment shows the Cmax, AUC0-6 and t1/2 values of 27 ng/mL, ≤ 29.7 ng h/mL and 0.33 hours, respectively[1] Animal Model: Female Sprague-Dawley rats[1] Dosage: 10 mg/kg Administration: P.o. (Pharmacokinetic Analysis) Result: The Cmax, AUC0-6 and Tmax were 27 ng/mL, ≤ 29.7 ng h/mL and 0.33 hours, respectively.
|
| References |
[1]. Busby RW, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344(1):196-206.
|
